Application of isoxazoline substituted benzamide derivative in prevention and treatment of animal parasites

By using isoxazoline-substituted benzamide derivatives to contact parasites, the problem of insecticide resistance was solved, achieving effective control of a variety of parasites and reducing parasite activity and mortality.

CN118924747APending Publication Date: 2024-11-12SHANDONG ACHIEVE TESTING TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310516822.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-09
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing commercial insect repellents have become less effective due to the long-term use of them, which has led to resistance in animal parasites.

Method used

The composition may contain surfactants, solid diluents, and liquid diluents, and may be administered via oral, gastrointestinal, or injection routes. It may be made by contacting parasites or their environment with an insecticidally effective amount of the compound, including its stereoisomers, racemates, tautomers, nitrogen oxides, or pharmaceutically acceptable salts.

Benefits of technology

It effectively prevents and controls a variety of animal parasites, including invertebrate parasites and endoparasites, reduces parasite activity and mortality, and reduces harm to animals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924747A_ABST
    Figure CN118924747A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of prevention and treatment of animal parasites, and particularly relates to an isoxazoline substituted benzamide derivative as shown in a formula (I). # imgabs0 #, and the compound shown in the formula (I) shows good activity on various animal parasites. Moreover, the compounds can obtain a good prevention and treatment effect at a very low dosage, so that the compounds can be used for preventing and treating animal parasites.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of preventing and controlling animal parasites, and specifically relates to application of isoxazoline-substituted benzamide derivatives in preventing and controlling animal parasites. Background Art

[0002] In animal health, the control of animal parasites is very important. Due to the long-term use of many commercial anthelmintics, pests have gradually developed resistance to these biological control agents, resulting in unsatisfactory control effects. Therefore, the development of methods that can more effectively control animal parasites is an important demand.

[0003] Patent CN111909143B discloses isoxazoline compounds represented by formula (I) as insecticides and acaricides.

[0004]

[0005] R1 and R2 are the same or different and are independently selected from F or Cl;

[0006] R3 and R4 are the same or different and are independently selected from H, Cl or CF3, and R3 and R4 are not H at the same time;

[0007] X1 and X2 are independently selected from CH or N, and X1 and X2 are not CH or N at the same time;

[0008] n is selected from 1 or 2.

[0009] The method of the present invention is not disclosed in this publication. Summary of the invention

[0010] The present invention provides a method for protecting animals from parasites, comprising administering to the animals an insecticidal effective amount of a compound represented by formula (I), a stereoisomer, a racemate, a tautomer, a nitrogen oxide, or a pharmaceutically acceptable salt thereof,

[0011]

[0012] Wherein, R1 and R2 are the same or different and are independently selected from F or Cl;

[0013] R3 and R4 are the same or different and are independently selected from H, Cl or CF3, and R3 and R4 are not H at the same time;

[0014] X1 and X2 are independently selected from CH or N, and X1 and X2 are not CH or N at the same time;

[0015] n is selected from 1 or 2;

[0016] According to an embodiment of the present invention: In formula (I),

[0017] X1 is CH, X2 is N;

[0018] R1 and R2 are the same or different and are independently selected from F or Cl;

[0019] R3 and R4 are the same or different and are independently selected from H, Cl or CF3, and R3 and R4 are not H at the same time;

[0020] n is selected from 1 or 2.

[0021] According to an embodiment of the present invention: In formula (I),

[0022] X1 is N, X2 is CH;

[0023] R1 and R2 are the same or different and are independently selected from F or Cl;

[0024] R3, R4 are the same or different and are independently selected from Cl or CF3;

[0025] n is selected from 1 or 2.

[0026] As an example, the compound of formula (I) is selected from the following compounds,

[0027]

[0028] Table 1

[0029] Number <![CDATA[X1]]> <![CDATA[X2]]> <![CDATA[R1]]> <![CDATA[R2]]> <![CDATA[R3]]> <![CDATA[R4]]> n 1. CH N Cl Cl H Cl 1 2. CH N F F H Cl 1 3. CH N Cl Cl <![CDATA[CF3]]> H 1 4. CH N F F <![CDATA[CF3]]> H 1 5. CH N Cl Cl <![CDATA[CF3]]> Cl 1 6. CH N F F <![CDATA[CF3]]> Cl 1 7. CH N Cl Cl Cl Cl 1 8. CH N F F Cl Cl 1 9. N CH Cl Cl Cl <![CDATA[CF3]]> 1 10. N CH F F Cl <![CDATA[CF3]]> 1 11. N CH Cl Cl Cl Cl 1 12. N CH F F Cl Cl 1 13. N CH Cl Cl Cl H 1 14. N CH F F Cl H 1 15. CH N Cl Cl H Cl 2 16. CH N F F H Cl 2 17. CH N Cl Cl <![CDATA[CF3]]> H 2 18. CH N F F <![CDATA[CF3]]> H 2 19. N CH Cl Cl Cl <![CDATA[CF3]]> 2 20. N CH F F Cl <![CDATA[CF3]]> 2

[0030] According to an embodiment of the present invention, the parasite is an invertebrate parasite.

[0031] According to an embodiment of the present invention, the method is a non-therapeutic method.

[0032] According to an embodiment of the present invention, the method is to contact the parasite or its environment with an insecticidally effective amount of the compound represented by formula (I), its stereoisomers, racemates, tautomers, nitrogen oxides, or pharmaceutically acceptable salts thereof.

[0033] The present invention also provides a non-therapeutic method for controlling parasite infestation, which comprises contacting the parasite or its environment with an insecticidally effective amount of a compound represented by formula (I), its stereoisomers, racemates, tautomers, nitrogen oxides, or pharmaceutically acceptable salts thereof.

[0034] The present invention also provides the use of the compound represented by formula (I), its stereoisomers, racemates, tautomers, nitrogen oxides, or pharmaceutically acceptable salts thereof in the preparation of drugs for preventing and controlling animal parasites.

[0035] The present invention also relates to such methods, wherein the parasite or its environment is contacted with a composition comprising a biologically effective amount of a compound of formula (I), a stereoisomer, racemate, tautomer, nitrogen oxide, or a pharmaceutically acceptable salt thereof, and at least one additional component selected from a surfactant, a solid diluent, and a liquid diluent, and the composition optionally further comprises a biologically effective amount of at least one additional biological compound or agent.

[0036] The present invention also provides a method for treating, preventing, inhibiting and / or killing external and / or internal parasites, the method comprising applying an insecticidally effective amount of a compound of formula (I), its stereoisomers, racemates, tautomers, nitrogen oxides or pharmaceutically acceptable salts thereof (e.g., compositions described herein) to an animal and / or on an animal. The present invention also relates to such methods, wherein an insecticidally effective amount of a compound of formula (I), its stereoisomers, racemates, tautomers, nitrogen oxides or pharmaceutically acceptable salts thereof (e.g., compositions described herein) is applied to an environment where the animal lives (e.g., a corral or blanket).

[0037] According to an embodiment of the present invention, the administration route is oral administration or enteral administration.

[0038] According to an embodiment of the present invention, the method of administration is injection.

[0039] According to an embodiment of the present invention, the animal is a vertebrate.

[0040] According to an embodiment of the present invention, the animal is a mammal, a bird or a fish.

[0041] According to an embodiment of the present invention, the mammal is a human.

[0042] According to an embodiment of the present invention, the mammal is livestock.

[0043] According to an embodiment of the present invention, the mammal is a canine.

[0044] According to an embodiment of the present invention, the mammal is a feline.

[0045] According to an embodiment of the present invention, the parasite is an ectoparasite.

[0046] According to an embodiment of the present invention, the parasite is an endoparasite.

[0047] According to an embodiment of the present invention, the parasite is a helminth.

[0048] According to an embodiment of the present invention, the parasite is an arthropod.

[0049] According to an embodiment of the present invention, the parasite is a fly, a mosquito, a mite, a tick, a lice, a flea, a bed bug, an assassin bug and / or a maggot.

[0050] According to an embodiment of the present invention, the parasite is a cat flea, a red tick, a soft tick, a bed bug, a mite, a fly, a mosquito, a maggot, or an assassin bug.

[0051] According to an embodiment of the present invention, the animal is a cat or a dog, and the parasite is a flea, a tick or a mite.

[0052] According to an embodiment of the present invention, the method of administration is oral administration twice a year.

[0053] According to an embodiment of the present invention, the method of administration is oral administration once a month.

[0054] According to an embodiment of the present invention, the method of administration is oral administration twice a month.

[0055] The embodiments of the invention may be combined in any of the ways described above.

[0056] The present invention also provides a composition for protecting animals from parasites, comprising as an active ingredient one, two or more of the compound represented by formula (I) described in any one of the above items, its stereoisomers, racemates, tautomers, nitrogen oxides or pharmaceutically acceptable salts thereof.

[0057] According to an embodiment of the present invention, the composition further comprises at least one additional ingredient selected from a surfactant, a solid diluent and a liquid diluent, and the composition optionally further comprises at least one additional biologically active compound or agent.

[0058] The present invention includes a method for preparing a composition for protecting animals from invertebrate parasites, which comprises mixing one, two or more of the compound of formula (I), its stereoisomers, racemates, tautomers, nitrogen oxides or pharmaceutically acceptable salts thereof with at least one pharmaceutically or veterinarily acceptable carrier.

[0059] Those skilled in the art are aware of pyridine heterocycles that can form nitrogen oxides. Synthetic methods for preparing pyridine heterocycle nitrogen oxides are well known to those skilled in the art and include oxidation of the compounds using peroxyacids such as peracetic acid and meta-chloroperbenzoic acid, hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane.

[0060] Those skilled in the art know that, because the salt of compound is in balance with their corresponding non-salt form under environment and physiological conditions, salt and non-salt form have common biological use. The various salts of formula (I) structure compound can be used to control invertebrate pests and animal parasites. The salt of the compound of formula (I) includes the acid addition salt with inorganic acid or organic acid such as hydrobromic acid, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, acetic acid, butyric acid, fumaric acid, lactic acid, maleic acid, malonic acid, oxalic acid, propionic acid, salicylic acid, tartaric acid, 4-methylbenzenesulfonic acid or valeric acid.

[0061] The composition of the compound of formula (I) may also contain adjuvants and additives known to those skilled in the art as formulation adjuvants (some of which are solid diluents, liquid diluents or surfactants). Such formulation adjuvants and additives may control: pH (buffers), foaming during processing (defoamers, such as polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), microbial growth (antimicrobial agents), product freezing (antifreeze agents), color (dye / pigment dispersions), elution (film formers or adhesives), evaporation (evaporation inhibitors), and other formulation properties. Film formers include, for example, polyvinyl acetate, polyvinyl acetate copolymers, polyvinyl pyrrolidone-vinyl acetate copolymers, polyvinyl alcohol, polyvinyl alcohol copolymers, and waxes.

[0062] Methods of using a compound of formula (I) in combination with at least one other invertebrate parasite control active ingredient. Such methods wherein the other invertebrate parasite control active ingredient has a different site of action than the compound of formula (I). In some cases, a combination with at least one other invertebrate parasite control active ingredient having a similar control range but a different site of action will be advantageous for resistance management. Thus, the composition consisting of the compound of formula (I) useful in the methods of the present invention further comprises a biologically effective amount of at least one additional invertebrate parasite control active ingredient having a similar control range but a different site of action.

[0063] A method of application involves spraying an aqueous dispersion or refined oil solution of a compound of formula (I). Combinations with spray oils, spray oil concentrates, viscous spreading agents, adjuvants, other solvents, and synergists such as piperonyl butoxide can enhance the efficacy of the compound. Such sprays can be applied from spray containers such as cans, bottles, or other containers, via a pump or by releasing them from pressurized containers such as pressurized aerosol spray cans. Such spray compositions can take a variety of forms, such as sprays, mists, foams, smoke, or dust mists. Such spray compositions can also include propellants, foaming agents, etc. The spray composition includes a biologically effective amount of a compound of formula (I) or a composition and a carrier. Representative propellants include, but are not limited to, methane, ethane, propane, butane, isobutane, butylene, pentane, isopentane, neopentane, pentene, hydrofluorocarbons, chlorofluorocarbons, dimethyl ether, and the aforementioned mixtures. A spray composition for controlling at least one invertebrate parasite selected from mosquitoes, black mosquitoes, deer flies, horse flies, wasps, hornets, vespas, ticks, spiders, ants, etc., including various pests or combinations thereof.

[0064] Controlling animal parasites includes controlling external parasites that parasitize on the surface of the host animal body (e.g., shoulders, armpits, abdomen, inner thighs) and internal parasites that parasitize on the host animal body (e.g., stomach, intestines, lungs, veins, subcutaneous, lymphatic tissue). External parasitic or disease-transmitting pests include, for example, chiggers, ticks, lice, mosquitoes, flies, mites and fleas. Internal parasites include heartworms, hookworms and worms. The compounds and compositions of formula (I) are particularly suitable for resisting external parasites. The compounds and compositions of formula (I) are suitable for systemic and / or non-systemic control of infestation or infection caused by parasites to animals.

[0065] The compounds and compositions of formula (I) are suitable for combating invertebrate parasites that parasitize animals, including those wild animals, livestock, and agricultural working animals. The term livestock used refers to domesticated animals raised in an agricultural environment to produce, for example, food or fiber, or to obtain their labor; livestock include cattle, sheep, goats, horses, pigs, donkeys, camels, buffaloes, rabbits, hens, turkeys, ducks, and geese. By combating parasites, mortality is reduced and reduced earnings are alleviated.

[0066] The compounds and compositions of formula (I) are particularly suitable for combating invertebrate parasites that are parasites of companion animals and pets (e.g. dogs, cats, pet birds and ornamental fish), research and experimental animals (e.g. hamsters, guinea pigs, rats and mice), and animals kept in zoos, wild habitats and / or circuses.

[0067] In embodiments of the present invention, the animal is preferably a vertebrate and more preferably a mammal, bird or fish. In a specific embodiment, the animal object is a mammal (including great apes, such as humans). Other mammal objects include primates (such as monkeys), bovines (such as cattle or cows), swine (such as domestic pigs or wild boars), ovines (such as goats or sheep), equines (such as horses), canines (such as dogs), felines (such as house cats), camels, deer, donkeys, buffaloes, antelopes, rabbits and rodents (such as guinea pigs, squirrels, rats, mice, gerbils and hamsters). Birds include ducks (swans, ducks and geese), columbidae (such as turtledoves and pigeons), pheasants (such as partridges, grouse and turkeys), galliformes (such as chickens), parrots (such as parakeets, macaws and parrots), game birds and ratites (such as ostriches).

[0068] For the purposes of the present invention, the term "fish" includes teleost fish, i.e., bony fish. The orders Salmonidae (including the family Salmonidae) and Perciformes (including the family Acanthidae) are both included in the teleost fish. Examples of possible fish receptors include the families Salmonidae, Plaiceidae, Cichlidae, and Acanthidae, among others.

[0069] The method of the present invention also includes marsupials (such as kangaroos), reptiles (such as farmed turtles), and other economically important livestock for which the method of the present invention can safely and effectively treat or prevent parasitic infections or infestations.

[0070] Examples of invertebrate parasites controlled by applying an insecticidally effective amount of a compound of formula (I) to the animal to be protected include ectoparasites (arthropods, mites, etc.) and endoparasites (helminths, such as nematodes, trematodes, tapeworms, acanthocephala, etc.).

[0071] Diseases or a class of diseases generally described as helminthiasis are attributed to infection of animal hosts with parasitic worms known as helminths. The term "helminths" is intended to include nematodes, flukes, tapeworms, and acanthocephalian worms. Helminthiasis is a problem associated with domesticated animals such as pigs, sheep, horses, cattle, goats, dogs, cats, and poultry.

[0072] Among helminths, a class of worms described as nematodes can cause widespread and serious infections in many types of animals. Nematodes treated by the compounds of the present invention and the methods of the present invention include the following genera: Acanthocheilus, Catstrongylus, Ancylostoma, Angiostrongylus, Gallinarum, Ascaris, Brugia, Bunostomum, Capillaria, Chabelli, Cooperia, Ringworm, Dictyocaulus, Diplocaulus, Diplocephalus, Diphyllobothrium, Dirofilaria, Dracunculia, Enterobius, Filarial, Haemonchus, Heterochaetes, Rabbits Ascaris, Loa, Manson, Mueller, Plate-stomach, Neck-necked, Nodular, Gastrotrichum, Oxycauda, ​​Parafilaria, Parascaris, Bubble-winged, Protostrongylus, Bristle, Spirulina, Crown, Strongyloides, Strongyloides, Sucking nematodes, Toxocara, Toxocara, Trichinella, Trichostrongylus, Trichostrongylus, Trichostrongylus, Whipworm, Hookworm and Wuchereria.

[0073] The most common nematode genera that can infect the above animals are Haemonchus, Trichostrongylus, Osterleghornsis, Acanthocera, Cooperia, Ascaris, Bunostomum, Nodularia, Chabaudia, Trichuris, Strongyloides, Trichinella, Dictyocaulus, Capillaria, Heterakis, Toxocara, Gallinarum, Oxyura, Ancylostoma, Uncinaria, Toxocara, and Parascaris. Some of these, such as Acanthocera, Cooperia, and Nodularia, mainly attack the intestines, while others, such as Haemonchus and Osterleghornsis, are more prevalent in the stomach, and others, such as Dictyocaulus, are present in the lungs. Other parasites are also located in other tissues, such as the heart and blood vessels, subcutaneous tissue, and lymphatic tissue.

[0074] Trematodes treated by the compounds and methods of the present invention include the following genera: Diplopyralis, Dipylidium, Spirotrema and Taenia.

[0075] The most common genera of parasites of the human gastrointestinal tract are Ancylostoma, Desmostrombus, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris, and Enterobius. Other genera of medical importance that reside in the blood or other tissues and organs outside the gastrointestinal tract are filarial worms such as Wuchereria, Brugia, Onchocerca and Loa and Dracunculiasis, as well as other intestinal roundworms of the genera Strongyloides and Trichinella.

[0076] The compounds of formula (I) are effective against a variety of animal ectoparasites (eg, arthropod ectoparasites of mammals and birds).

[0077] Insect and acarid pests include, for example, biting insects such as flies and mosquitoes, mites, ticks, lice, fleas, stink bugs, parasitic maggots and the like.

[0078] Adult flies include, for example, horn flies or blood flies, horse flies or horse flies, stable flies or stable flies, black flies or black flies, deer flies or spotted flies, lice flies or plant lice, and tsetse flies or tsetse flies. Parasitic fly maggots include, for example, skin flies (stomach flies and mad flies), blow flies or blow flies, spinner fly maggots or spinner fly larvae, cow hide flies or heel flies, wool fly maggots, and horse bot maggots. Mosquitoes include, for example, Culex pipiens, Anopheles, and Aedes.

[0079] Mites include mites of the Mesostigmata suborder, for example, mesostigma mites such as bird mites and Dermanyssus gallinae; scabies or itch mites, for example, Sarcoptes types, such as human scabies; animal itch mites, for example, Itch mites, including cattle foot mites and sheep itch mites; chiggers, for example, Trombicidal types, such as North American chiggers and True Trombiculidae.

[0080] Ticks include, for example, soft-bodied ticks, including Cryptorhynchus types, such as Acutus types and Ornithodoros types; hard-bodied ticks, including Ixodes types, such as Rhipicephalus sanguineus, Dermacentor variabilis, Dermacentor andersoni, Amblyomma americanum, Ixodes scissus and other Rhipicephalus types (including the former genus Bosporus).

[0081] Lice include, for example, blood-sucking lice such as the genus Brachyptera and the genus Bovis; biting lice such as the genus Haematopus, the genus Gnaphaloptera and the genus Bryopus.

[0082] Fleas include, for example, Ctenocephalides types such as dog fleas (ctenocephalides canis) and cat fleas (ctenocephalides felis); Xenopsylla types such as oriental fleas (xenopsylla cheopis); and Phlebia types such as human fleas (pulex irritans).

[0083] Stink bugs include, for example, Cimex lectularius or, for example, the common stink bug (Cimex lectularius); types of the subfamily Assassininae, including assassin bugs also known as assassin bugs; for example, Echinops rubripes and Triatomine bugs.

[0084] Flies, fleas, lice, mosquitoes, mites, ticks and worms cause enormous losses to the livestock and companion animal sectors. Arthropod parasites are also troublesome to humans and can be vectors of disease-causing organisms for both humans and animals.

[0085] Numerous other invertebrate parasitic pests are known in the art and may also be treated with the compounds of formula (I).

[0086] In particular, the compounds of formula (I) are particularly effective against external parasites, including stable flies; ticks such as Ixodes types, Boophilus types, Rhipicephalus types, Amblyomma types, Dermestrum types, Hyalomma types, and Haemaphysalis types; and fleas, such as cat fleas (ctenocephalides felis) and dog fleas (ctenocephalides canis).

[0087] The compounds of formula (I) are also effective against ectoparasites, including flies such as Haematobiairritans (horn flies), Simulium types (black mosquitoes), Glossina types (tsetse flies), Hydrotaeairritans (big-headed flies), Musca autumnalis (autumn housefly), Musca domestica (housefly), Morellia simplex (simple black fly), Tabanus types (horse flies), Bovine skin flies, Linear skin flies, Lucilia sericata, Lucilia cuprina (copper green fly), Culicoides types (blow flies), Neotropical stomata types, Oestrus ovis (sheep fly), Culicoides types (midges), horse flies, horse flies, red horse flies and horse nose flies; lice such as cattle hair lice (Pediculus spp.), horse hair lice, donkey blood lice, cat bird lice, dog lice, spiny jaw lice and dog gnawing lice; sheep tick flies such as sheep ticks; and mites such as Itch spp. types, Sarcoptes spp. types, Sarcoptes scabiei mites, cattle foot mites, horse demodex mites, Cheyletus spp. types, cat ear mites, Trombiculum spp. types and Otodectescyanotis (ear mites).

[0088] Other biologically active compounds or agents may be applied simultaneously or at different times with the compound of formula (I). Such compounds may be, for example, useful adjuvants in the composition of formula (I) of the method of the present invention. As described below, such biologically active compounds may be included in the composition of formula (I). Such biologically active compounds used in the present invention include organophosphate insecticides. Such insecticides have very wide activity as insecticides and have anthelmintic activity in some cases. Organophosphate insecticides include, for example, dicrotophos, terbufos, dimethoate, dipyraphos, disulfothion, trichlorfon, azinphos-methyl, chlorpyrifos, malathion, acephate, methylphosphine, acephate, ethyl parathion, methyl parathion, mefenphos, phorate, trithion and phosalone. The composition of the compound of formula (I) of the method of the present invention also includes carbamate insecticides and combinations with organochlorine insecticides, and the carbamate insecticides include, for example, carbaryl, chlorfenapyr, aldicarb, chlorfenapyr, ethoxycarb, chlorfenapyr, etc. Compositions of compounds of formula (I) also include combinations with biopesticides, including repellents, pyrethrins (and their synthetic variants, such as allethrin, pyrethrin, permethrin, tralomethrin) and nicotine, which is commonly used as a miticide. Other combinations are combinations with miscellaneous insecticides, including: Bacillus thuringiensis, chlorobenzene, formamidines (such as amitraz), copper compounds (such as copper hydroxide and copper oxychloride sulfate), cyhalothrin, cypermethrin, dicofol, endosulfan, cis-cypermethrin, cypermethrin, high tri-cyhalothrin, methoxychlor and sulfur.

[0089] Of note are additional biologically active compounds or agents selected from anthelmintics known in the art, such as avermectins (e.g., ivermectin, moxidectin, milbemycin), benzimidazoles (e.g., albendazole, triclobendazole), N-salicylanilides (e.g., closantel, hydroxyclozanide), substituted phenols (e.g., nitroiodobenzonitrile), pyrimidines (e.g., pyrantel), imidazole thiazoles (e.g., levamisole) and praziquantel.

[0090] Other biologically active compounds or agents that can be used in the composition of formula (I) of the present invention can be selected from insect growth regulators (IGR) and juvenile hormone analogs (JHA), such as diflubenzuron, cyfluthrin, fluzolan, cypermethrin, methoprene, etc., thereby providing initial and continuous control of parasites to the animal subject and the environment of the animal subject (at all stages of insect growth, including eggs). It is worth noting that the biologically active compounds or agents that can be used in the composition of formula (I) of the present invention are selected from avermectin antiparasitic compounds. As mentioned above, avermectin compounds include potent antiparasitic agents that are known to be useful against a wide spectrum of mammalian endoparasites and ectoparasites.

[0091] A preferred compound for use within the context of the present invention is ivermectin. Ivermectin is a semisynthetic derivative of avermectins and is generally prepared to be at least 80% 22,23-dihydroavermectin B. 1a and less than 20% 22,23-dihydro-avermectin B 1b mixture.

[0092] The treatment of the present invention can be applied externally by conventional methods, such as tablets, capsules, potions, infusion preparations, granules, pastes, boluses, feeding procedures or suppositories; or by parenteral administration, such as by injection (including intramuscular injection, subcutaneous injection, intravenous injection, intraperitoneal injection) or implantation; or by nasal administration.

[0093] The compounds of formula (I) may be administered in a controlled release form, for example a slow release formulation for subcutaneous or oral administration.

[0094] Typically, the parasiticidal composition according to the present invention comprises a mixture of a compound of formula (I), its nitrogen oxide or salt and one or more pharmaceutically or veterinarily acceptable carriers, the carrier comprising excipients and adjuvants, which are selected according to the intended route of administration (e.g. oral administration or parenteral administration such as injection) and according to standard practice. In addition, a suitable carrier is selected based on compatibility with one or more active ingredients in the composition, including, for example, considerations of relative stability to pH and water content. Therefore, it is worth noting that the composition for protecting animals from invertebrate parasites comprises a parasiticidally effective amount of a compound of formula (I) and at least one carrier.

[0095] For parenteral administration (including intravenous injection, intramuscular injection and subcutaneous injection), the compound of formula (I) can be formulated into a suspension, solution or emulsion in an oily or aqueous carrier, and may contain adjuvants such as suspending agents, stabilizers and / or dispersants. The compound of formula (I) can also be formulated for bolus injection or continuous infusion. The pharmaceutical composition for injection includes an aqueous solution of the active ingredient (e.g., a salt of the active compound) in a water-soluble form, preferably in a physiologically compatible buffer containing other excipients or adjuvants as known in the field of pharmaceutical preparations. In addition, a suspension of the active compound can be prepared in a lipophilic carrier. Suitable lipophilic carriers include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or substances such as liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol or dextran. The preparation for injection can be present in a unit dosage form, such as an ampoule container or a multidose container. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, eg, sterile pyrogen-free water, before use.

[0096] In addition to the above-mentioned preparations, the compound of formula (I) can also be formulated into a long-acting preparation. Such long-acting preparations can be administered by inoculation (e.g., subcutaneous or intramuscular) or by intramuscular injection or subcutaneous injection. With regard to this route of administration, the compound of formula (I) can be formulated with an appropriate polymeric material or hydrophobic material (e.g., in an emulsion containing a pharmaceutically acceptable oil) and an ion exchange resin, or the compound can be formulated into a slightly soluble derivative such as, but not limited to, a slightly soluble salt.

[0097] For administration by inhalation, the compound of formula (I) can be delivered in an aerosol spray form using a pressurized pack or sprayer and a suitable propellant such as, without limitation, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane or carbon dioxide. For pressurized aerosols, the dosage unit can be controlled by providing a valve to deliver a quantitative amount. Gelatin capsules and cartridges for inhalers or insufflators can be formulated to contain a powder mix of the compound and a suitable powder base such as lactose or starch.

[0098] The compounds of formula (I) surprisingly have favorable pharmacokinetic and pharmacodynamic properties, providing systemic availability by oral administration and ingestion. Therefore, after ingestion by the animal to be protected, the parasiticidal effective concentration of the compound of formula (I) in the blood can protect the treated animal from the infringement of blood-sucking pests such as fleas, wall moths and moths. It is therefore worth noting that the oral form of the composition (i.e., in addition to the parasiticidal effective amount of the compound of formula (I), also includes one or more carriers, the carrier being selected from a binder and filler suitable for oral administration and a concentrated feed carrier) that protects animals from invertebrate parasites.

[0099] For oral administration in the form of solutions (the most readily available absorption form), emulsions, suspensions, pastes, gels, capsules, tablets, boluses, powders, granules, rumen retentions and food / water / lick bricks, the compounds of formula (I) can be formulated with binders / fillers known in the art suitable for oral compositions, such as sugars and sugar derivatives (e.g., lactose, sucrose, mannitol, sorbitol), starches (e.g., corn starch, wheat starch, rice starch, potato starch), cellulose and derivatives (e.g., methylcellulose, carboxymethylcellulose, ethylhydroxycellulose), protein derivatives (e.g., zein, gelatin), and synthetic polymers (e.g., polyvinyl alcohol, polyvinyl pyrrolidone). If necessary, lubricants (e.g., magnesium stearate), disintegrants (e.g., cross-linked polyvinyl throlidine, agar, alginic acid) and dyes or pigments can be added. Pastes and gels also typically contain binders (e.g., acacia, alginic acid, bentonite, cellulose, xanthan gum, colloidal magnesium aluminum silicate) to help keep the composition in contact with the oral cavity and not easily discharged.

[0100] A preferred embodiment is a composition of the present invention formulated into a chewable and / or edible product (e.g., a chewable treat or edible tablet). Such a product will ideally have a taste, texture, and / or aroma that is pleasing to the animal to be protected to facilitate oral administration of the compound of formula (I).

[0101] If the parasiticidal composition is in the form of a concentrated feed, the carrier is usually selected from high-performance feed, feed cereals or concentrated proteins. In addition to the parasiticidal active ingredients, such compositions comprising concentrated feed also contain additives that can promote animal health or growth, improve the quality of meat from slaughtered animals or can be used in animal husbandry. These additives include, for example, vitamins, antibiotics, chemotherapeutic agents, bacteriostats, fungistats, coccidiostats and hormones.

[0102] The compounds of formula (I) may also be formulated in rectal compositions such as suppositories or retention enemas, using, for example, conventional suppository bases such as coconut oil or other glycerides.

[0103] The formulations used in the methods of the present invention may contain an antioxidant, such as BHT (butylated hydroxytoluene). The antioxidant is generally present in an amount of 0.1% to 5% (weight / volume). Some formulations require a solubilizing agent such as oleic acid to dissolve the active agent, especially when spinosad is included. Common spreading agents used in these pour-on formulations include isopropyl myristate, isopropyl palmitate, saturated C 12 -C 18 Caprylic / capric anhydride of fatty alcohols, oleic acid, oleyl esters, ethyl oleate, triglycerides, silicone oils and dipropylene glycol methyl ether. Pour-on formulations for use in the method of the present invention can be prepared according to known techniques. When the pour-on formulation is a solution, the "parasiticide" / insecticide is mixed with the carrier or vehicle using heating and stirring (if necessary). Auxiliary or additional ingredients can be added to the mixture of active agent and carrier, or they can be mixed with the active agent before adding the carrier. Pour-on formulations in the form of emulsions or suspensions can be prepared similarly using known techniques.

[0104] Other delivery systems for more hydrophobic drug compounds can be used. Liposomes and emulsions are examples of well-known delivery vehicles or carriers for hydrophobic drugs. In addition, organic solvents such as dimethyl sulfoxide can be used if desired.

[0105] The amount of application required for effective control of invertebrate parasites (i.e., "insecticidally effective amount") will depend on factors such as the following: the type of invertebrate parasite to be controlled, the life cycle of the pest, the life stage, its size, location, time of year, host crop or animal, feeding behavior, mating behavior, ambient moisture, temperature, etc. It is easy for those skilled in the art to determine the insecticidally effective amount required to achieve the desired degree of invertebrate parasite control. Generally speaking, for veterinary applications, the compound or composition of formula (I) is applied to animals to be protected from invertebrate parasites, especially warm-blooded animals, in an insecticidally effective amount. The insecticidally effective amount is the amount of active ingredient required to achieve the observed effect of reduced occurrence or activity of the target invertebrate parasite. Those skilled in the art will know that the insecticidally effective dose may vary depending on the compounds and compositions used in the method of the present invention, the desired insecticidal effect and duration, the target invertebrate parasite species, the animal to be protected, the mode of application, etc., and the amount required to achieve a specific effect can be determined by simple experiments.

[0106] In terms of oral or parenteral administration to animals, the dosage of the compounds of the invention used at suitable intervals is generally in the range of about 0.01 mg / kg to about 100 mg / kg, and preferably in the range of about 0.01 mg / kg to about 30 mg / kg of animal body weight. The compounds of the invention are suitable for administration to animals at intervals ranging from about once a day to about once a year. It is worth noting that the administration interval is within the range of about once a week to about once every 6 months. It is particularly worth noting that the administration interval is once a month (i.e., the compound is administered to animals once a month).

[0107] Beneficial Effects

[0108] The compounds shown in formula I show good activity against a variety of animal parasites. Moreover, these compounds can achieve good control effects at very low dosages, and therefore can be used to control animal parasites.

[0109] Definition and explanation of terms

[0110] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by those skilled in the art to which the subject matter of the claims pertains. Unless otherwise indicated, all patents, patent applications, and publications cited herein are incorporated herein by reference in their entirety. If there are multiple definitions of a term herein, the definition in this chapter shall prevail.

[0111] It should be understood that references (including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4 THDefinitions of standard chemical terms can be found in ED." Vols. A (2000) and B (2001), Plenum Press, New York). Unless otherwise stated, conventional methods within the technical scope of the art, such as mass spectrometry, NMR, IR and UV / Vis spectroscopy and pharmacological methods, are used. Unless specific definitions are provided, the terms used in the relevant descriptions of analytical chemistry, organic synthetic chemistry, and drugs and medicinal chemistry herein are known in the art. Standard techniques can be used in chemical synthesis, chemical analysis, drug preparation, formulation and delivery, and treatment of patients. For example, the manufacturer's instructions for the use of the kit, or in a manner known in the art or the description of this application, the reaction and Purification is performed. The above techniques and methods can be implemented according to conventional methods well known in the art, usually according to the descriptions in the multiple general and more specific documents cited and discussed in this specification. In this specification, groups and substituents thereof can be selected by those skilled in the art to provide stable structural parts and compounds. When substituents are described by conventional chemical formulas written from left to right, the substituents also include chemically equivalent substituents obtained when the structural formula is written from right to left, as long as they comply with the valence bond rules. For example, CH2O is equivalent to OCH2, and the carbon atoms of oxygen atoms or methylene groups can be connected to the substitution position.

[0112] The term "pharmaceutically acceptable salt" as used herein refers to a salt that retains the biological effectiveness of the free acid and free base of the specified compound and has no adverse effects in biology or other aspects. The compounds of the present application also include pharmaceutically acceptable salts, such as nitrates, hydrochlorides, sulfates, phosphates, acetates, trifluoroacetates, malates or citrates, etc., which are generally used in the field of agriculture and horticulture. Pharmaceutically acceptable salts refer to the conversion of the basic group in the parent compound into a salt form. Pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic groups such as amine (amino) groups. The pharmaceutically acceptable salts of the present application can be synthesized from the parent compound, that is, the basic group in the parent compound is reacted with 1-4 equivalents of acid in a solvent system. Suitable salts are listed in Remington's Pharmaceutical Scicences, 17 th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), e.g., the hydrochloride salt.

[0113] As used herein, "stereoisomer" refers to an isomer resulting from a different arrangement of atoms in a molecule in space. The compounds of formula (I) contain asymmetric or chiral centers and therefore exist in different stereoisomeric forms. All stereostructures of formula (I) are intended to be separated into individual diastereomers based on their different physicochemical properties using well-known methods, for example, enantiomers can be separated by reaction with appropriate optically active substances (e.g., chiral alcohols or Mosher's acid chlorides) to convert them into diastereomers, which are separated and converted (e.g., hydrolyzed) to the corresponding single isomers. Some compounds in formula (I) may be atropisomers (e.g., substituted aromatic groups) and are also part of this application. Enantiomers may also be separated using chiral chromatographic columns. The compounds in formula (I) may exist in different tautomeric forms, all of which are included within the scope of this application. For example, compounds in the form of keto-enol and imine-enamine.

[0114] As used herein, the terms "pests", "invertebrate pests" and "invertebrate parasites" include arthropods, gastropods and nematodes that are of economic importance as pests. The term "arthropod" includes insects, mites, spiders, scorpions, centipedes, millipedes, ball bugs and syngenes. The term "gastropod" includes snails and other stalked eyes. The term "nematodes" includes all worms, such as roundworms, heartworms and phytophagous nematodes (Nematoda), flukes (Trematoda), acanthocephalians and tapeworms (Cestoda).

[0115] "Controlling invertebrate pests" means inhibiting the growth of invertebrate pests and related expressions may be defined similarly.

[0116] A parasite "infestation" is the presence of a large number of parasites that are dangerous to humans or animals. The infestation may be present in the environment (e.g., housing, bedding, and surrounding property or structures of humans or animals), on crops or other types of plants, or on the skin or fur of animals. When the infestation is present in an animal (e.g., in the blood or other internal tissues), the term "infection" is generally understood in the art unless otherwise indicated. The term "infestation" is also synonymous with the term "infection."

[0117] The compounds of formula (I) may exist in the form of one or more stereoisomers. Various stereoisomers include enantiomers, diastereomers and atropisomers. Those skilled in the art will appreciate that when one stereoisomer is enriched relative to other stereoisomers or when it is separated from other stereoisomers, it may be more active and / or may exhibit beneficial effects. In addition, those skilled in the art know how to separate, enrich and / or selectively prepare the stereoisomers. The compounds of formula (I) may exist as a mixture of stereoisomers, a single stereoisomer, or as an optically active form. DETAILED DESCRIPTION

[0118] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.

[0119] The following tests demonstrate the control efficacy of compounds of formula (I) against specific pests. "Control efficacy" means the efficacy of inhibiting the development of invertebrate parasites, resulting in a significant reduction in feeding (including mortality). However, the pest control protection provided by the compounds is not limited to these species. See Table 2 for compound descriptions.

[0120] Compound Examples

[0121] Table 2

[0122]

[0123]

[0124]

[0125] The preparation methods of the compounds in Table 2 are disclosed in patent CN111909143B. In case it is necessary to provide the preparation methods of the compounds of formula (I), this patent publication is incorporated herein by reference.

[0126] Biological Activity Assay Example

[0127] Test Example 1: To evaluate the control effect on cat fleas, mice were orally administered with a test compound dissolved in propylene glycol / cyclohexane (60:40) at a dose of 10 mg / kg. Two hours after the oral administration of the test compound, approximately 8 to 16 adult fleas were applied to each mouse. Then, 48 hours after the fleas were applied to the mice, the mortality rate of the fleas was evaluated.

[0128] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0129] Test Example 2: To evaluate the control effect on cat fleas, mice were orally administered with a test compound dissolved in propylene glycol / glycerol ether (60:40) at a dose of 10 mg / kg. 24 hours after the oral administration of the test compound, approximately 8 to 16 adult fleas were applied to each mouse. Then, 48 hours after the fleas were applied to the mice, the mortality rate of the fleas was evaluated.

[0130] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0131] Test Example 3: To evaluate the control effect on cat fleas, mice were subcutaneously injected with a test compound dissolved in propylene glycol / cyclohexane (60:40) at an amount of 10 mg / kg. Two hours after the subcutaneous injection of the test compound, about 8 to 16 adult fleas were applied to each mouse. Then, 48 hours after the fleas were applied to the mice, the mortality rate of the fleas was evaluated.

[0132] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0133] Test Example 4: To evaluate the control effect on cat fleas, the test compound was dissolved in propylene glycol / glycerol ether (60:40) and then diluted in bovine blood to a final test concentration of 30 ppm. The treated blood was placed in a tube and the bottom of the tube was covered with a film. About 10 adult cat fleas were allowed to pass through the film to feed on the treated blood. Then, after 72 hours, the mortality rate of adult cat fleas was evaluated.

[0134] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0135] Test Example 5: To evaluate the control effect on R. sanguineus, beagles were orally administered a test compound dissolved in propylene glycol / cyclohexylglycerol (60:40) at a dose of 10 mg / kg. Two hours after the oral administration of the test compound, 20 R. sanguineus were applied to each beagle for infestation. Then, 48 hours after the R. sanguineus were applied to the beagles, the R. sanguineus were counted to evaluate the mortality of the R. sanguineus.

[0136] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0137] Test Example 6: To evaluate the control effect on R. sanguineus, beagles were subcutaneously injected with a test compound dissolved in propylene glycol / cyclohexylglycerol (60:40) at a dose of 10 mg / kg. Two hours after the subcutaneous injection of the test compound, 20 R. sanguineus were applied to each beagle for infestation. Then, 48 hours after the R. sanguineus were applied to the beagles, the R. sanguineus were counted to evaluate the mortality of the R. sanguineus.

[0138] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0139] Test Example 7: To evaluate the control effect on soft ticks (O. moubata), the test compound was dissolved in propylene glycol / glycerol ether (60:40) and 10 mg / kg body weight of the compound was orally administered to treat six guinea pigs. All guinea pigs were topically infested with juvenile soft ticks (O. moubata) before treatment. Ten well-fed ticks were collected 24 hours after infestation to evaluate the percentage of killed individuals and the mortality rate of soft ticks was evaluated.

[0140] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0141] Test Example 8: To evaluate the control effect on soft ticks (O. moubata), the test compound was dissolved in propylene glycol / glycerol ether (60:40) and 10 mg / kg body weight of the compound was administered subcutaneously to treat six guinea pigs. All guinea pigs were topically infested with juvenile soft ticks before treatment. Ten well-fed ticks were collected 24 hours after infestation to evaluate the percentage of killed individuals and the mortality rate of soft ticks.

[0142] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0143] Test Example 9: To evaluate the control effect on soft ticks (O. moubata), the test compound was dissolved in propylene glycol / glycerol ether (60:40), and 10 mg / kg body weight of the compound was intraperitoneally administered to treat six guinea pigs. All guinea pigs were topically infested with juvenile soft ticks before treatment. Ten well-fed ticks were collected 24 hours after infestation to evaluate the percentage of killed individuals and the mortality rate of soft ticks.

[0144] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0145] Test Example 10: To evaluate the control effect on bed bugs (C. lectularius), the test compound was dissolved in propylene glycol / glycerol ether (60:40), and 10 mg / kg body weight of the compound was orally administered to treat six guinea pigs. All guinea pigs were topically infested with bed bugs before treatment. Ten full bed bugs of each type were collected 24 hours after infestation to evaluate the percentage of killed individuals. The mortality rate of bed bugs was evaluated.

[0146] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0147] Test Example 11. To evaluate the control effect on bed bugs (C. lectularius), the test compound was dissolved in propylene glycol / glycerol ether (60:40), and 10 mg / kg body weight of the compound was subcutaneously administered to treat six guinea pigs. All guinea pigs were topically infested with bed bugs before treatment. Ten full bed bugs of each type were collected 24 hours after infestation to evaluate the percentage of killed individuals. The mortality rate of bed bugs was evaluated.

[0148] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0149] Test Example 12: To evaluate the control effect on bed bugs (C. lectularius), the test compound was dissolved in propylene glycol / glycerol ether (60:40), and 10 mg / kg body weight of the compound was intraperitoneally administered to treat six guinea pigs. All guinea pigs were topically infested with bed bugs before treatment. Ten full bed bugs of each type were collected 24 hours after infestation to evaluate the percentage of killed individuals. The mortality rate of bed bugs was evaluated.

[0150] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0151] Test Example 13: To evaluate the control effect on mites (M. musculinus), the test compound was dissolved in propylene glycol / cyclohexylglycerol (60:40), and then all mice were infested with mites, including all stages of the parasite. The mice were divided into three per group and treated with the test compound at 10 mg / kg body weight subcutaneously. Then, 24 hours after applying the mites to the mice, the mites were counted and the mortality rate of the mites was evaluated.

[0152] Of the compounds tested, the following compounds had at least 80% control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0153] Test Example 14: To evaluate the control effect on mites (M. musculinus), the test compound was dissolved in propylene glycol / cyclohexylglycerol (60:40), and then all mice were infested with mites, including all stages of the parasite. The mice were divided into three per group and treated with 10 mg / kg body weight of the test compound orally. Then, 24 hours after the mites were applied to the mice, the mites were counted and the mortality rate of the mites was evaluated.

[0154] Of the compounds tested, the following compounds had at least 80% control: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0155] Test Example 15: To evaluate the fly control effect, beagles were orally administered a test compound dissolved in propylene glycol / glycerol ether (60:40) at a dose of 10 mg / kg. Two hours after the oral administration of the test compound, approximately 20 flies were administered to each beagle. Then, 48 hours after the administration of the flies to the beagle, the flies were counted and the mortality rate of the flies was evaluated.

[0156] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0157] Test Example 16: To evaluate the control effect on flies, beagles were subcutaneously injected with a test compound dissolved in propylene glycol / glycerol ether (60:40) at a dose of 10 mg / kg. Two hours after the subcutaneous injection of the test compound, approximately 20 flies were applied to each beagle. Then, 48 hours after the flies were applied to the beagles, the flies were counted and the mortality of the flies was evaluated.

[0158] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0159] Test Example 17: To evaluate the mosquito control effect, a test compound dissolved in propylene glycol / glycerol (60:40) was orally administered to cats at a dose of 10 mg / kg. Two hours after the oral administration of the test compound, approximately 30 mosquitoes were applied to each cat. Then, 48 hours after the mosquitoes were applied to the cats, the mosquitoes were counted and the mortality rate of the mosquitoes was evaluated.

[0160] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0161] Test Example 18: To evaluate the control effect on mosquitoes, a test compound dissolved in propylene glycol / glycerol (60:40) was subcutaneously injected into cats at 10 mg / kg. Two hours after the subcutaneous injection of the test compound, about 30 mosquitoes were applied to each cat. Then, 48 hours after the mosquitoes were applied to the cats, the mosquitoes were counted and the mortality rate of the mosquitoes was evaluated.

[0162] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0163] Test Example 19: To evaluate the control effect on maggots, a test compound dissolved in propylene glycol / glycerol (60:40) was orally administered to cats at a dose of 10 mg / kg. Two hours after the oral administration of the test compound, approximately 20 maggots were administered to each cat. Then, 48 hours after the administration of the maggots to the cats, the maggots were counted and the mortality rate of the maggots was evaluated.

[0164] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0165] Test Example 20: To evaluate the control effect on maggots, a test compound dissolved in propylene glycol / glycerol (60:40) was subcutaneously injected into cats at an amount of 10 mg / kg. Two hours after the subcutaneous injection of the test compound, about 20 maggots were applied to each cat. Then, 48 hours after the maggots were applied to the cats, the maggots were counted and the mortality rate of the maggots was evaluated.

[0166] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0167] Test Example 21: To evaluate the control effect on assassin bugs, a test compound dissolved in propylene glycol / glycerol (60:40) was orally administered to cats at an amount of 10 mg / kg. Two hours after the oral administration of the test compound, approximately 30 assassin bugs were administered to each cat. Then, 48 hours after the administration of the assassin bugs to the cats, the assassin bugs were counted and the mortality rate of the assassin bugs was evaluated.

[0168] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0169] Test Example 22: To evaluate the control effect on assassin bugs, a test compound dissolved in propylene glycol / glycerol ether (60:40) was subcutaneously injected into cats at an amount of 10 mg / kg. Two hours after the subcutaneous injection of the test compound, about 30 assassin bugs were applied to each cat. Then, 48 hours after the assassin bugs were applied to the cats, the assassin bugs were counted and the mortality rate of the assassin bugs was evaluated.

[0170] Of the compounds tested, the following caused at least 80% mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

[0171] The above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for protecting an animal from invertebrate parasites, the method comprising administering to the animal an insecticidally effective amount of a compound of formula (I), a stereoisomer, a racemate, a tautomer, a nitrogen oxide or a pharmaceutically acceptable salt thereof, in, R 1 , R 2 The same or different, independently selected from F or Cl; R 3 , R 4 The same or different, independently selected from H, Cl or CF 3 , and R 3 , R 4 Not at the same time H; X 1 , X 2 are independently selected from CH or N, and X 1 With X 2 Not CH or N at the same time; n is selected from 1 or 2.

2. The method according to claim 1, It is characterized in that In formula (I), X 1 For CH, X 2 is N; R 1 , R 2 The same or different, independently selected from F or Cl; R 3 , R 4 The same or different, independently selected from H, Cl or CF 3 , and R 3 , R 4 Not at the same time H; n is selected from 1 or 2.

3. The method according to claim 1, It is characterized in that In formula (I), X 1 N, X 2 for CH; R 1 , R 2 The same or different, independently selected from F or Cl; R 3 , R 4 The same or different, independently selected from Cl or CF 3 ; n is selected from 1 or 2.

4. The method according to any one of claims 1 to 3, It is characterized in that The compound of formula (I) is selected from the following compounds, 5. The method according to any one of claims 1 to 4, It is characterized in that The method described is a non-therapeutic method; Preferably, the method comprises contacting the parasite or its environment with an insecticidally effective amount of a compound of formula (I), a stereoisomer, a racemate, a tautomer, a nitrogen oxide, or a pharmaceutically acceptable salt thereof.

6. The method according to any one of claims 1 to 5, It is characterized in that The administration route is oral administration or enteral administration; Preferably, the method of administration is injection.

7. The method according to any one of claims 1 to 6, wherein the parasite is an invertebrate parasite; Preferably, the parasite is an ectoparasite; Preferably, the parasite is an endoparasite; Preferably, the parasite is a helminth; Preferably, the parasite is an arthropod; Preferably, the parasite is a fly, mosquito, mite, tick, lice, flea, bed bug, assassin bug and / or maggot; Preferably, the parasite is cat flea, red tick, soft tick, bed bug, mite, fly, mosquito, maggot, assassin bug; Preferably, the animal is a vertebrate; Preferably, the animal is a mammal, bird or fish; Preferably, the mammal is a human; Preferably, the mammal is livestock; Preferably, the mammal is a canine; Preferably, the mammal is a feline; Preferably, the animal is a cat or a dog and the parasite is a flea, a tick or a mite.

8. A non-therapeutic method for controlling parasite infestation, the method comprising contacting the parasite or its environment with an insecticidally effective amount of a compound of formula (I) as described in any one of claims 1 to 4, its stereoisomers, racemates, tautomers, nitrogen oxides, or pharmaceutically acceptable salts thereof.

9. Use of the compound of formula (I) as claimed in any one of claims 1 to 4, its stereoisomers, racemates, tautomers, nitrogen oxides, or pharmaceutically acceptable salts thereof in the preparation of a medicament for preventing and controlling animal parasites.

10. A composition for protecting an animal from invertebrate parasites, It is characterized in that The composition comprises as an active ingredient one, two or more of the compound represented by formula (I) according to any one of claims 1 to 4, its stereoisomers, racemates, tautomers, nitrogen oxides or pharmaceutically acceptable salts thereof.